TY - JOUR
T1 - Expert consensus document from the European Society of Cardiology on catheter-based renal denervation
AU - Mahfoud, Felix
AU - Lüscher, Thomas Felix
AU - Andersson, Bert
AU - Baumgartner, Iris
AU - Cifkova, Renata
AU - DiMario, Carlo
AU - Doevendans, Pieter
AU - Fagard, Robert
AU - Fajadet, Jean
AU - Komajda, Michel
AU - LeFèvre, Thierry
AU - Lotan, Chaim
AU - Sievert, Horst
AU - Volpe, Massimo
AU - Widimsky, Petr
AU - Wijns, William
AU - Williams, Bryan
AU - Windecker, Stephan
AU - Witkowski, Adam
AU - Zeller, Thomas
AU - Böhm, Michael
PY - 2013/7/21
Y1 - 2013/7/21
N2 - Current evidence from the available clinical trials strongly support the notion that catheter-based radiofrequency ablation of renal nerves reduces blood pressure and improves blood pressure control in patients with drug-treated resistant hypertension, with data now extending out to 36 months. Accordingly, renal denervation can be considered as a therapeutic option in patients with resistant hypertension, whose blood pressure cannot be controlled by a combination of lifestyle modification and pharmacological therapy according to current guidelines. The fact that renal denervation also reduces whole-bodysympathetic nerve activity suggests that this therapy may also be beneficial in other clinical states characterized by sympathetic nervous system activation-this may ultimately lead to new indications.
AB - Current evidence from the available clinical trials strongly support the notion that catheter-based radiofrequency ablation of renal nerves reduces blood pressure and improves blood pressure control in patients with drug-treated resistant hypertension, with data now extending out to 36 months. Accordingly, renal denervation can be considered as a therapeutic option in patients with resistant hypertension, whose blood pressure cannot be controlled by a combination of lifestyle modification and pharmacological therapy according to current guidelines. The fact that renal denervation also reduces whole-bodysympathetic nerve activity suggests that this therapy may also be beneficial in other clinical states characterized by sympathetic nervous system activation-this may ultimately lead to new indications.
UR - http://www.scopus.com/inward/record.url?scp=84880136056&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880136056&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/eht154
DO - 10.1093/eurheartj/eht154
M3 - Article
C2 - 23620497
AN - SCOPUS:84880136056
VL - 34
SP - 2149
EP - 2157
JO - European Heart Journal
JF - European Heart Journal
SN - 0195-668X
IS - 28
ER -